The Effects of Exercising Muscle Mass on Post Exercise Hypotension

Total Page:16

File Type:pdf, Size:1020Kb

The Effects of Exercising Muscle Mass on Post Exercise Hypotension Journal of Human Hypertension (2000) 14, 317–320 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE The effects of exercising muscle mass on post exercise hypotension JR MacDonald, JD MacDougall and CD Hogben Departments of Kinesiology and Medicine, McMaster University, Hamilton, Ontario L8S 4K1, Canada Nine recreationally active, borderline hypertensive sub- the effect to be prolonged following the leg exercise. We jects completed 30 min of arm ergometry (ARM) at 65% conclude that the mass of the working muscle does not V˙ O2 peak and 30 min of leg ergometry (LEG) at 70% directly effect the magnitude of post-exercise hypoten- V˙ O2 Peak (randomised order). Blood pressure was moni- sion (PEH) but may influence the duration of the tored before and for 1 h after exercise using the Fin- response. These results suggest that a central mech- apres method. Systolic, diastolic and mean blood press- anism or decreased vascular responsiveness is respon- ures were significantly reduced for the entire 1 h post sible for PEH. exercise. This reduction was independent of exercise Journal of Human Hypertension (2000) 14, 317–320 modality, but there was an indication for the duration of Keywords: blood pressure; ergometry; Finapres Introduction Subjects and methods The mechanism(s) responsible for post-exercise Subjects hypotension (PEH) has not been established. Studies Nine recreationally active participants (seven males, examining both peripherally1–3 and centrally4–7 two females), with borderline hypertension (five mediated mechanisms have produced inconsistent screening measurements of 135 Ͼ systolic blood results. pressure Ͻ 150 and/or 85 Ͼ diastolic blood pressure At the same relative percentage of limb-specific Ͻ 95 mm Hg) volunteered to participate in this ˙ VO2 Peak, arm and leg ergometry are known to elicit study. Subjects had a mean age of 23 ± 4 (mean ± similar blood pressure and heart rate responses.8 It s.d.) years, a mean height of 176 ± 13 cm and a mean has been estimated that the mass of the upper limbs weight of 77.4 ± 7.5 kg. Average body mass index account for approximately 7.6% of the body’s mass, was similar between the males (24.74) and females whereas the lower limbs account for approximately (24.67) and listed within the ‘healthy range’.10 The 32%.9 Thus at the same relative exercise intensity, McMaster University Human Ethics Committee the total active muscle mass and absolute metabolic approved the study and subjects were advised of the rate would be greater for leg ergometry than for arm risks before providing written informed consent. ergometry. It also follows that while intramuscular concentration of metabolites and ions (eg, adenosine and K+) would be similar for the two modes of exer- Preliminary testing cise, the absolute production of these vasodilator The Finapres system was used to measure blood substances and release into the circulation would be pressure in this study. We have recently discussed greatest with leg ergomety. Therefore, one might the accuracy of the resting Finapres measures fol- hypothesise that if PEH is mediated by some periph- lowing exercise (see MacDonald et al).11 On five sep- eral factor, leg ergometry would be expected to arate days, participants were required to undergo result in a greater decline in blood pressure. It was resting Finapres blood pressure measurement after felt that by examining the influence of the exercising a seated period of 20–30 min. The five systolic and muscle mass, some insight may be provided as to five diastolic blood pressures were averaged and 1 the mechanism responsible for PEH. standard deviation (s.d.) was calculated. If, during one of the experimental trials, initial resting press- ure (either systolic or diastolic) was not within 1 s.d. of the subject’s pre-trial average, the test was termin- ated and rescheduled for another day. Prior to beginning the study, limb-specific maxi- mal oxygen uptake was determined using incremen- Correspondence: Jay R MacDonald, Departments of Kinesiology tal arm and leg ergometry tests to exhaustion. Both and Medical Sciences, Ivor Wynne Centre, McMaster University, Hamilton, Ontario L8S 4K1, Canada tests used an electrically braked cycle/arm erg- Received 20 August 1999; revised 30 November 1999; accepted ometer (Eric Jaeger, Hoechberg, Germany). During 28 December 1999 each test, subjects exercised at a cadence greater Muscle mass and hypotension JR MacDonald et al 318 than 60 revolutions per min (rpm). At the com- form and the lowest point in the waveform prior to pletion of each 2-min interval, the power output was the last inflection point, respectively. Mean arterial increased by 20–60 Watts, dependent on the limbs pressure (MAP) was determined by the quotient of used and state of fatigue. Volitional exhaustion was the integrated pressure and the duration of the deemed to be the point at which subjects could no time interval. longer maintain a cadence of 60 rpm. The mean of All blood pressure variables were assessed using the two consecutive highest oxygen uptake values single, two-factor, repeated measures, analyses of was considered the limb-specific V˙ O2 Peak. Expired variance (ANOVA) with trial and time of measure- gas was collected using a one-way air flow valve ment as the repeated measures. The Tukey Honestly (Hans Rudolph #2700, Hans Rudolph Inc, Kansas Significant Difference (HSD) method was used to City, MO, USA) and analysed on-line via an IBM identify the location of any significant differences. compatible computer using the TurboFit software A probability level of P р 0.05 was considered stat- package (Vacumetrics, Ventura, CA, USA) coupled istically significant. All values are expressed as with an AMETEK S3A/1 oxygen analyser (Applied mean ± s.d. unless otherwise stated. Electrochemistry, Pittsburg, PA, USA) and a Hewlett Packard 78356A carbon dioxide analyser (Hewlett Results Packard, Mississauga, ON, Canada). Both analysers were calibrated prior to and following each test The effects of exercise on post-exercise blood press- using gases of known O2 and CO2 content. ure are illustrated in Figure 1. No differences were Limb-specific V˙ O2 Peak was 30.96 mL kg min for found between ARM or LEG trials. Collectively, SBP arm exercise (ARM) and 46.81 mL kg min for leg was significantly (F(6,48) = 5.64, P Ͻ 0.01) reduced exercise (LEG). Although the original intent was to from pre-exercise values between 5 and 60 min post- have subjects perform each exercise session at 70% exercise inclusive. The pressure decrement was con- ෂ of limb-specific V˙ O2 Peak, initial trials demonstrated stant at 15 mm Hg below pre-exercise values that most subjects could only maintain arm ergome- (140 ± 12 mm Hg) for the entire post-exercise moni- try at 65% of V˙ O2 Peak. Therefore a revised 65% and toring. DBP was also decreased for the entire post- = Ͻ 70% of the limb-specific V˙ O2 Peak was calculated for exercise period (F(6,48) 3.28, P 0.01). The nadir the ARM and LEG trials respectively as the target of DBP occurred at 45 min post exercise (82 ± 13 vs oxygen consumption during the submaximal exer- 73 ± 11), and collectively fluctuated no more than 3 cise trials. mm Hg during the post-exercise period. Subjects refrained from exercising during the 24 h MAP also remained below pre-exercise values for prior to testing and consumed no stimulants or the entire hour post exercise (F(6,48) = 3.70, P Ͻ depressants known to affect blood pressure (eg, caf- feine and alcohol). Protocol After a 4 h fast, the subjects reported to the labora- tory and remained quietly seated for 30 min. They then underwent resting Finapres blood pressure measurements verified by auscultation. The Fina- pres transducer was placed at mid-sternal level and coupled to an on-line data acquisition package (Windaq/200, DataQ Instruments Inc, Akron, OH, USA) sampling at a frequency of 300 Hz. Calibration of the Finapres was completed using an internal calibration sequence as well as a mercury man- ometer. The transducer was calibrated to show a lin- ear response between 0 and 300 mm Hg. On separate days, subjects were required to perform 30 min of arm ergometry at a power output that elicited 65% of arm V˙ O2 Peak, and 30 min of leg ergometry at a power output that elicited 70% of leg V˙ O2 Peak (randomised order). Finapres blood pressure was monitored continu- ously throughout the session with 2-min windows recorded at rest, 5, 10, 15, 30, 45 and 60 min post- exercise for subsequent analysis. Analysis Blood pressure waveforms were analysed using the Windaq data analysis software (DataQ Instruments Figure 1 The effects of 30 min of arm and leg exercise on post Inc). Systolic (SBP) and diastolic (DBP) blood press- exercise blood pressure (mean ± s.e.m.). *Indicates pooled data ure were calculated as the highest point in the wave- is significantly different from baseline. Post, min post exercise. Journal of Human Hypertension Muscle mass and hypotension JR MacDonald et al 319 seated rest.1 We are therefore confident that the dec- rements in blood pressure documented here are a result of the exercise interventions. This study indi- cates that the magnitude of the decrement in post- exercise blood pressure is not influenced by the mass of the working muscle. This would lend sup- port to two theories of post-exercise hypotension. Firstly, PEH may be mediated by factors originat- ing in the brain and cardiovascular control centres. Rodent work has suggested that the central opioid and serotonergic systems, leading to changes in sympathetic activity may be the source of PEH.6,7,12 However, studies examining these systems in humans are contradictory4,5 and have not been pur- sued in recent years.
Recommended publications
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Medication for Military Aircrew: Current Use, Issues
    RTO-TR-014 AC/323(HFM-014)TP/14 NORTH ATLANTIC TREATY ORGANIZATION RTO-TR-014 RESEARCH AND TECHNOLOGY ORGANIZATION BP 25, 7 RUE ANCELLE, F-92201 NEUILLY-SUR-SEINE CEDEX, FRANCE RTO TECHNICAL REPORT 14 Medication for Military Aircrew: Current Use, Issues, and Strategies for Expanded Options (les M´edicaments pour les equipages´ militaires : Consommation actuelle, questions et strat´egies pour des options elargies)´ Report of the Human Factors and Medicine Panel (HFM) Working Group 26. Published June 2001 Distribution and Availability on Back Cover 7KLVSDJHKDVEHHQGHOLEHUDWHO\OHIWEODQN 3DJHLQWHQWLRQQHOOHPHQWEODQFKH RTO-TR-014 AC/323(HFM-014)TP/14 NORTH ATLANTIC TREATY ORGANIZATION RESEARCH AND TECHNOLOGY ORGANIZATION BP 25, 7 RUE ANCELLE, F-92201 NEUILLY-SUR-SEINE CEDEX, FRANCE RTO TECHNICAL REPORT 14 Medication for Military Aircrew: Current Use, Issues, and Strategies for Expanded Options (les M´edicaments pour les equipages´ militaires : Consommation actuelle, questions et strat´egies pour des options elargies)´ Authors: EDIGER Mark, M.D. (US) Working Group Chairman BENSON, Alan J. (UK), DANESE, Daniele (IT), DAVIDSON, Ronald A., (CA), DOIREAU, Philippe (FR), ELIOPOULOS, Themis (GR), GRAY, Gary W. (CA), LAM, Berry (NL), NICHOLSON, Anthony A., (UK), PARIS, Jean-Fran¸cois, (FR), PICKARD, Jeb S., (US), PIERARD, C. (FR) Co-Authors: GOURBAT, Jean-Pierre (FR), LAGARDE, D. (FR), LALLEMENT G., (FR), PERES, M. (FR), RODIG,¨ E. (GE), STONE, Barbara M. (UK), TURNER, Claire (UK) Report of the Human Factors and Medicine Panel (HFM) Working Group 26. The Research and Technology Organization (RTO) of NATO RTO is the single focus in NATO for Defence Research and Technology activities. Its mission is to conduct and promote cooperative research and information exchange.
    [Show full text]
  • A Study on Beta Blockers - a Brief Review Tv
    IJRPC 2018, 8(4), 508-529 Namratha et al. ISSN: 22312781 INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Review Article A STUDY ON BETA BLOCKERS - A BRIEF REVIEW TV. Namratha*, KC. Chaluvaraju and AM. Anushree Department of Pharmaceutical Chemistry, Government College of Pharmacy, Bengaluru-560 027, Karnataka, India. ABSTRACT Beta blockers are agents or drugs which competitively inhibit the action of catecholamines at the beta adrenergic receptors, which are mainly used to treat variety of clinical conditions like angina, hypertension, asthma, COPD and arrhythmias. These drugs are also useful in several other therapeutic situations including shock, premature labor and opioid withdrawal, and as adjuncts to general anesthetics. These drugs produce their effect by interacting with the beta adrenergic receptors. In the present communication, an effort has been made to compile beta adrenergic receptors and the chemistry, discovery and development, classification and therapeutic applications of beta blockers. Keywords: Beta blockers, adrenergic receptors, catecholamines and aryloxypropanolamines. 1. INTRODUCTION Beta blockers were first developed by Sir 1.1 Adrenergic receptors James Black in 1962. The structures of The ability of a molecule to selectively these receptors have been studied by x- agonize or antagonize adrenergic ray crystallography.5 In the current article receptor made great advances in beta blockers are majorly focused with pharmacotherapeutics. The discovery of respect to their location, functions adrenergic receptors lead to major mediated, discovery and development, development of newer adrenergic SAR, classification, structures and agonists as well as antagonist.1 therapeutic applications. Adrenergic receptors are 7- transmembrane spanning receptors 1.2 Locations and agonistic action of beta which mediate both central and adrenergic receptors6 peripheral actions of the adrenergic The following are the various beta neurotransmitters.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • Pharmacotherapy for Mild Hypertension (Review) – the Cochrane Collaboration
    Pharmacotherapy for mild hypertension (Review) Diao D, Wright JM, Cundiff DK, Gueyffier F This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 11 http://www.thecochranelibrary.com Pharmacotherapy for mild hypertension (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. T A B L E O F C O N T E N T S HEADER ....................................... 1 ABSTRACT ...................................... 1 PLAIN LANGUAGE SUMMARY .............................. 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . 2 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS ....................................... 6 Figure 1. ..................................... 7 DISCUSSION ..................................... 8 Figure 2. ..................................... 9 AUTHORS’ CONCLUSIONS ............................... 10 ACKNOWLEDGEMENTS ................................ 10 REFERENCES ..................................... 10 CHARACTERISTICS OF STUDIES ............................. 13 DATA AND ANALYSES .................................. 19 Analysis 1.1. Comparison 1 Treatment versus No Treatment, Outcome 1 Mortality. 19 Analysis 1.2. Comparison 1 Treatment versus No Treatment, Outcome 2 Stroke. 20 Analysis 1.3. Comparison 1 Treatment versus No Treatment, Outcome 3 Coronary Heart Disease. 20 Analysis 1.4. Comparison 1 Treatment versus
    [Show full text]
  • Pharmacokinetics of Epanolol After Acute Andchronic Oral Dosing In
    Br. J. clin. Pharmac. (1990), 29, 333-337 Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris J. HOSIE', A. K. SCOPE2, J. C. PETRIE2 & I. D. COCKSHO1T3 'The Surgery, 1980 Great Western Road, Glasgow, G13 2SW, 2Clinical Pharmacology Unit, University of Aberdeen, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB9 2ZB and 3Safety of Medicines Department, ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG 1 Epanolol is a novel anti-anginal agent which is a 1 1-adrenoceptor partial agonist exhibiting selective 1l-adrenoceptor antagonist and selective 1l-adrenoceptor agonist activity. It is mainly metabolised to conjugates prior to excretion in urine and it was of interest to determine if any accumulation occurred in elderly patients. 2 The pharmacokinetics of epanolol have been studied over 72 h after a single oral dose of 200 mg and then over 24 h after 12 consecutive daily oral doses in 13 elderly patients with stable angina pectoris. 3 The peak plasma concentrations (mean ± s.d.) after the single dose (25.7 ± 17.0 ng ml-) were not significantly different (P = 0.35) from those at steady state (32.4 ± 20.9 ng ml-'). There was wide inter-individual variation on both occasions. The time to peak did not alter significantly during the study with mean values of 1.5 and 1.2 h on acute and chronic dosing respectively. 4 Plasma concentrations declined biphasically with a mean terminal phase half-life of 17 h and 5 fold inter-individual variation. 5 The mean area under the curve to 24 h was not significantly different (P = 0.26) after the single dose (59.0 ± 29.8 ng ml-' h) from that at steady state (78.4 ± 55.0 ng ml-1 h).
    [Show full text]
  • Effects of Pharmacological Exposure on Ovarian Cancer (EPOC)
    Sharp et al. Ovarian Pharmacoepidemiology ENCePP Protocol Effects of pharmacological exposure on Ovarian Cancer (EPOC) PROTCOL & ANALYSIS PLAN Project funded by Health Research Board Date: 01/08/2014 Version: V1.0 V1.0 PUBLIC ©NCRI 2014 Page 1 of 28 Sharp et al. Ovarian Pharmacoepidemiology ENCePP Protocol 1. Project Synopsis Project Title: Translating basic science into improved patient outcomes in ovarian cancer: an Ireland-UK collaboration investigating common pharmacological exposures and tumour characteristics, recurrence, survival and mortality. Research theme: Pharmacoepidemiology NCRI Staff Members: Mr Chris Brown, Dr Linda Sharp Funding source: Health Research Board Project duration: 2013 - 2015 Project Overview: By combining data from large pharmacoepidemiology databases in Ireland and the UK, will conduct a population-based study investigating associations between use of statins, beta-blockers and NSAIDs and ovarian cancer progression and outcome. This study will provide valuable population-based evidence on the effects of these common drugs on ovarian cancer and contribute to improved health outcomes for women affected by this cancer. Investigators: Dr Kathleen Bennett, Pharmacology & Therapeutics, Trinity College, St James’s Hospital Dublin Dr Thomas Ian Barron, Department of Pharmacology & Therapeutics, Trinity College Dublin Prof Liam Murray, Centre for Public Health, Queen’s University Belfast Dr John Coulter, Gynaecological Oncology, South Infirmary Victoria University Hospital, Cork Collaborators: Prof Carmel Hughes,
    [Show full text]